Published: Dec 16, 2023, 04:05 IST | Updated: Dec 16, 2023, 04:05 IST
Pfizer's shares take a nosedive after a disappointing forecast for next year, revealing that its ambitious $43 billion takeover of seagen may not be enough to counter the diminishing returns from its covid franchise.